Zosano Pharma Inc., of Fremont, Calif., and Asahi Kasei Pharma Corp. (AKP), of Tokyo, entered a long-term collaboration to develop, commercialize and supply a weekly transdermal patch formulation of Teribone (teriparatide acetate), AKP's formulation of human parathyroid hormone for the treatment of osteoporosis patients with a high risk of fracture.